7 completed, 3 recruiting, 2 not yet recruiting, 2 terminated. 15 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 7, Recruiting 3, Not yet recruiting 2, Terminated 2, Unknown 1 |
| Phase 2 | 6 | Completed 4, Recruiting 1, Terminated 1 |
Follow B-cell Malignancies: new trials by email Literature Review of B-cell Malignancies trials Research Report on B-cell Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0920 - Diffuse Large B-Cell Lymphoma, B-cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-12-11 | 2026-10-21 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0050 - Diffuse Large B-Cell Lymphoma, B-Cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-11-30 | 2026-10-19 |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-10-30 |
| Evaluation of SYS6005 in Patients With Advanced Malignant Tumor SYS6005 - B-cell Malignancies, Solid Tumors | Phase 1 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 132 | 2025-04-03 | 2025-05-14 |
| A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. AZD5492 - B-cell Malignancies | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 174 | 2024-09-18 | 2026-09-30 |
| A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies TT-01488 Tablets - B-Cell Malignancies | Phase 1 | Recruiting | TransThera Sciences (Nanjing), Inc. | 37 | 2023-03-30 | 2023-11-21 |
| Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies TT-01488 - B-Cell Malignancies | Phase 1 | Unknown | TransThera Sciences (Nanjing), Inc. | 37 | 2022-06-01 | 2022-06-09 |
| Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Zanubrutinib, Fluconazole, Diltiazem - B-cell Malignancies | Phase 1 | Completed | BeiGene | 26 | 2020-11-15 | 2024-10-26 |
| A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Parsaclisib, Itacitinib, Rituximab - B-Cell Malignancies | Phase 1 / Phase 2 | Completed | Incyte Corporation | 88 | 2016-09-22 | 2023-09-28 |
| Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Tirabrutinib, Idelalisib, Entospletinib - B-cell Malignancies | Phase 1 | Terminated | Gilead Sciences | 203 | 2015-06-16 | 2025-06-17 |
| A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Nivolumab, Epacadostat, Chemotherapy - B-cell Malignancies, Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Completed | Incyte Corporation | 307 | 2014-11-26 | 2025-08-14 |
| Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Zanubrutinib - B-cell Malignancies | Phase 1 / Phase 2 | Completed | BeiGene | 385 | 2014-09-04 | 2022-04-28 |
| Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies INCB040093, INCB040093 + itacitinib - B-cell Malignancies | Phase 1 | Completed | Incyte Corporation | 121 | 2013-06-30 | 2026-05-11 |
| Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Urelumab, Rituximab - B-Cell Malignancies | Phase 1 | Completed | Bristol-Myers Squibb | 47 | 2013-03-01 | 2017-03-31 |
| A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies MEDI-551, Rituximab - B-cell Malignancies, Cancer | Phase 1 / Phase 2 | Completed | MedImmune LLC | 136 | 2010-04-16 | 2020-05-13 |
Leukemia, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Colorectal Neoplasms (1) · Glioblastoma (1) · Head and Neck Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Melanoma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Recurrence (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Lymphoma, B-Cell (2) · Adnexal Diseases (1) · Astrocytoma (1)
Rituximab (3) · INCB039110 (2) · itacitinib (2) · zanubrutinib (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Carboplatin (1) · Clarithromycin (1) · Diltiazem (1) · Drug Therapy (1) · Etoposide (1) · Fluconazole (1) · Ifosfamide (1) · Nivolumab (1) · Voriconazole (1) · epacadostat (1)
Incyte Corporation (3) · BeOne Medicines (2) · BeiGene (2) · TransThera Sciences (Nanjing), Inc. (2) · AstraZeneca (1) · Bristol-Myers Squibb (1) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1) · Gilead Sciences (1) · MedImmune LLC (1) · Shenzhen Geno-Immune Medical Institute (1)
United States (9) · China (4) · Australia (3) · Italy (3) · United Kingdom (3) · Canada (2) · France (2) · Spain (2) · Belgium (1) · Denmark (1) · Germany (1) · Japan (1) · New Zealand (1) · South Korea (1)
Claudia Corrado, M.D. (1) · Lance Leopold (1) · Li Jianyong (1) · Lung-Ji Chang, PhD (1) · Nitin Jain, MD (1) · Peter Langmuir, MD (1) · Qiu Lugui, Ph.D (1) · Xu Wei (1)
PMID 28178345, PMID 29695516, PMID 30444200, PMID 30803990, PMID 34152395, PMID 35390135, PMID 35900694, PMID 36480811, PMID 38502198, PMID 38775302, PMID 39563886
2016 (2), 2009 (1), 2015 (1)